HK1200330A1 - Romidepsin and 5 - azacitidine for use in treating lymphoma - Google Patents

Romidepsin and 5 - azacitidine for use in treating lymphoma Download PDF

Info

Publication number
HK1200330A1
HK1200330A1 HK15100777.2A HK15100777A HK1200330A1 HK 1200330 A1 HK1200330 A1 HK 1200330A1 HK 15100777 A HK15100777 A HK 15100777A HK 1200330 A1 HK1200330 A1 HK 1200330A1
Authority
HK
Hong Kong
Prior art keywords
azacitidine
romidepsin
methods
treating lymphoma
disclosed
Prior art date
Application number
HK15100777.2A
Other languages
English (en)
Chinese (zh)
Inventor
萊因哈德．達默
莱因哈德．达默
西馬．羅薩迪
西马．罗萨迪
Original Assignee
细胞基因公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 细胞基因公司 filed Critical 细胞基因公司
Publication of HK1200330A1 publication Critical patent/HK1200330A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK15100777.2A 2011-09-23 2012-09-21 Romidepsin and 5 - azacitidine for use in treating lymphoma HK1200330A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161538734P 2011-09-23 2011-09-23
US61/538,734 2011-09-23
US201261698441P 2012-09-07 2012-09-07
US61/698,441 2012-09-07
PCT/US2012/056485 WO2013043967A1 (en) 2011-09-23 2012-09-21 Romidepsin and 5 - azacitidine for use in treating lymphoma

Publications (1)

Publication Number Publication Date
HK1200330A1 true HK1200330A1 (en) 2015-08-07

Family

ID=47045157

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15100777.2A HK1200330A1 (en) 2011-09-23 2012-09-21 Romidepsin and 5 - azacitidine for use in treating lymphoma

Country Status (12)

Country Link
US (1) US20130085115A1 (enExample)
EP (1) EP2758067A1 (enExample)
JP (1) JP2014526558A (enExample)
KR (1) KR20140069225A (enExample)
CN (1) CN104114182A (enExample)
AU (1) AU2012312308B2 (enExample)
CA (1) CA2849708A1 (enExample)
HK (1) HK1200330A1 (enExample)
IL (1) IL231636A0 (enExample)
MX (1) MX2014003467A (enExample)
WO (1) WO2013043967A1 (enExample)
ZA (1) ZA201402151B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015195634A1 (en) * 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
WO2018009855A1 (en) * 2016-07-07 2018-01-11 MiRagen Therapeutics, Inc. Methods for treating cutaneous t-cell lymphoma (ctcl) with mir-155 inhibitors
WO2021186855A1 (ja) * 2020-03-16 2021-09-23 株式会社マンダム Ｔ細胞性リンパ腫の指標の検出方法、及びその利用

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
GB8817743D0 (en) 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
JPH064872A (ja) 1992-06-19 1994-01-14 Sony Corp 光ディスク再生装置
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
AU2001280109A1 (en) 2000-09-01 2002-03-22 Fujisawa Pharmaceutical Co. Ltd. A method of producing fr901228
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
EP1482418A1 (en) 2003-05-28 2004-12-01 Sap Ag A data processing method and system
ES2444890T3 (es) * 2006-03-31 2014-02-27 Erasmus University Medical Center Rotterdam Nueva composición para el control del crecimiento tumoral
US20100137239A1 (en) * 2006-04-24 2010-06-03 Gloucester Pharmaceuticals Gemcitabine combination therapy
CA2654566A1 (en) * 2006-06-09 2007-12-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
US20110269699A1 (en) * 2008-10-24 2011-11-03 Mitchell Keegan Cancer therapy

Also Published As

Publication number Publication date
ZA201402151B (en) 2015-06-24
MX2014003467A (es) 2014-07-30
CN104114182A (zh) 2014-10-22
EP2758067A1 (en) 2014-07-30
CA2849708A1 (en) 2013-03-28
WO2013043967A1 (en) 2013-03-28
US20130085115A1 (en) 2013-04-04
IL231636A0 (en) 2014-05-28
AU2012312308A1 (en) 2013-05-02
AU2012312308B2 (en) 2015-11-19
KR20140069225A (ko) 2014-06-09
JP2014526558A (ja) 2014-10-06
NZ622752A (en) 2016-06-24

Similar Documents

Publication Publication Date Title
MX2010003299A (es) Oligonucleotidos muy cortos (micromirs).
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
IL198591A0 (en) Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
GB2449027B (en) Devices, systems and methods for medicament delivery
IL212114A0 (en) Drug delivery methods, structures, and compositions for nasolacrimal system
WO2012078593A3 (en) Lysophosphatidic acid receptor antagonists and their use in the treatment fibrosis
GB0910105D0 (en) Devices, systems and methods for medicament delivery
CL2007003774A1 (es) Compuestos derivados de quinazolina sustituidos, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, aterosclerosis y artritis.
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
WO2012061469A3 (en) Crystalline forms of pralatrexate
IN2012DN02177A (enExample)
IN2012DN02730A (enExample)
ZA200805939B (en) Azacyclyl-substituted aryldihydroisoquinolinones, process for their preparation and their use as medicaments
IN2012DN00754A (enExample)
IL198289A (en) Processed dihydropyrazolones, processes for their preparation, medicinal preparations containing them and their use in the preparation of medicinal preparations
WO2011113060A3 (en) Antiviral compounds and methods of use thereof
GB2478085B (en) Devices, systems and methods for medicament delivery
IL217500A0 (en) Tetrazole derivatives, their preparartion and pharmaceutical compositions containing them
MX2009012598A (es) Formas de dosis que comprenden vx-950 y su regimen de dosificacion.
AR062658A1 (es) Terapias de combinacion para artritis reumatoide
IL207205A0 (en) Triazolopyridazines as par1 inhibitors, their preparation and use as medicaments
IL197732A (en) A system for packaging intravenous pharmaceutical preparations and kits containing them
IL192454A (en) Solid Pharmaceuticals Containing S-Adenosylmethionine
MX2009001433A (es) Nucleosidos para suprimir o reducir el desarrollo de resistencia en terapia citostatica.
HK1200330A1 (en) Romidepsin and 5 - azacitidine for use in treating lymphoma